On the advice of my counsel I’ve been told I should post

New Post Public Reply Private Reply Replies (4) Message Board
Respert24
1,454
On the advice of my counsel I’ve been told I should post an otherwise private email I wrote this morning on the subject of company-wide silence and the optimism surrounding it. Can we poke holes in it? Are we looking at things incorrectly because of our seat on a gravy train with biscuit wheels? I don’t think so. Here’s what I wrote.

To me, there are a couple key factors that render just about any bashing viewpoint worthless.

Samsung hasn't been paid.

You can't afford to lose Samsung. While it would suck to have our existing inventory go to waste because of the FDA and our delay in getting to market, you can't risk having to start from scratch with another manufacturer moving forward. They've said it's a year or more just to get a facility approved and capable of manufacturing LL. Management thinks we'll need LL as soon as the end of the year thanks to approval(s). Even if we're on their back burner and won't be ready to have them start cranking out more LL until later this year, we need them paid in full. Cocked, locked, and ready to rock, as Dame Judy Dench famously says.

If you haven't paid Samsung but you've moved ahead with other costly endeavors, like paying the bond for Amarex, all signs point toward them making Samsung whole. They also said as much in an 8k back in early January, I think. Bankruptcy maneuvers wouldn't include financing your Amarex bond, continuing your trials in Brazil, and planning to make your overdue payments to your manufacturing partner.

Amarex bond was paid

From everything I know, and despite nothingspecial's insistence that this silence is all about Amarex, the only thing we're really getting out of this is their physical records (which Recknor worked with trial sites to rebuild anyway) and a chance to audit them. The audit will give us the ammunition to both, avoid paying what they claim we owe, and to go after damages for their piss poor efforts on our behalf. The company wouldn't have to stay silent because of that. They may have to stay silent ABOUT that, but not about Nash and Samsung and literally every other thing the company is up to that has nothing to do with Amarex. Maybe you could argue that there are some ties to Nash data that they want a closer look at before they release things to the public, but that doesn't really hold water. They released the 350mg and planned to release the 700mg all while they knew where the Amarex situation was headed.

Paying the bond, including the weird way in which they chose to do it, are clear signals that Cytodyn is continuing to work toward their goal of Leronlimab approvals.

Brazil trials are still ongoing and new hospitals have been joining

In what world where you have no money and are behind the eight ball do you continue to fund those trials? You could stop them and divert the money to Samsung or efforts to get the HIV BLA submitted. Or to start the LH trial, which could be a relatively cheap and quick route to an approval. In other words, you shut down efforts during a crisis and they aren't doing that. Except for delaying the LH trial, of course. If it’s actually delayed and not purposely held up, that is. But up through the end of the year they were working toward submitting new BTD requests for metastasis and Nash, all while talking about aggressively seeking partnerships. Nothing really happened between then and early to mid January that could have stopped it all dead in its tracks in lieu of bankruptcy.

Shares unsold plus the current share price

It's business 101 that you need money to run your business. They have lots of shares, even if those shares are worth less than at any point in the last year and a half. You have a tanking share price and you owe people money. Yes, it's not the most enviable situation. But they have shares to sell and data to release, and they've done neither. Either they are the world's dumbest people, or there' something brewing behind the scenes that they know will take care of those problems.

Any counterclaim to this silence being positive can be trumped with "then release the Nash data" or "sell some shares, that's what they're for." Because that's what you do when you need money and/or want to keep your share price from eroding.

I think the only reasonable scenario that involves a less rosy outlook than a big-time partnership, would be if this silence results in a shitty deal that doesn't really move the needle that much, and just barely keeps us afloat. “Thailand's 75th largest pharmaceutical company that nobody has heard of, which only has 11 employees, partners with Cytodyn to commercialize Leronlimab for Nash in Asia.”

You know, the Vyera of Thailand. Where the former CEO is in jail for running an illegal big game hunting business. Can you imagine all this shit going down and when they finally sign a deal it’s with Janky Pete’s Pfarma, based out of some weird combination grocery store/fishing supply/pharma business in some Thai village somewhere?

I can’t either. Well, I can, but only because we’ve witnessed a long streak of underwhelming “surprises”. There are a lot of companies like Vyera out there, and I worry more about a deal with an un-influential pharma company for a disappointing amount than I do no deal at all.

Or another bummer would be a buyout offer for $10 or less, which I still think isn't plausible when they can just license something and sell shares. But weirder things have happened. Maybe the board and management are just sick of the battle.


CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 44

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 21

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 107

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 11

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 94

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 13

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 86

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading

Top 5 Most Recently Viewed Articles

Russel Metals Announces Conference Call Plans for Q3 2024

Updated Category News Views 80

Join the Discussion: Russel Metals Q3 2024 Conference Call Russel Metals Inc. presents an opportunity for investors and stakeholders to engage in dialogue regarding their third quarter performance in 2024. The conference call is scheduled to take place shortly after the release of the results, ensuring a comprehensive overview of the company's financial status. Conference...

Continue Reading
Investors Urged to Act in Fluor Corporation Securities Case

Updated Category News Views 358

Investors Urged to Act in Fluor Corporation Securities Case Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., has issued an important reminder to investors regarding the Fluor Corporation (NYSE: FLR). If you experienced losses exceeding $100,000 by purchasing Fluor's securities within a specific timeframe, you have a limited window to...

Continue Reading
Exploring Consumer Product Risks: Insights from Legal Experts

Updated Category News Views 186

Investigation into Defective Consumer Products The Law Offices of Jason Turchin is currently investigating various claims related to defective consumer products that can potentially harm individuals. These products include commonly used items such as space heaters and HVAC systems, as well as kitchen equipment like coffee makers and pressure cookers. Each of these items...

Continue Reading
Empowering Older Adults: Take Action to Prevent Falls Today

Updated Category News Views 71

Empowering Older Adults to Prevent Falls Every year, millions of older adults fall, leading to serious injuries and long-term health complications. The upcoming Falls Prevention Awareness Week is designed to educate people on how to reduce these risks. This initiative focuses on making resources easily accessible and encourages community involvement, helping seniors live...

Continue Reading
Sealed Air Corporation Announces Significant Cash Dividend

Updated Category News Views 173

Sealed Air Corporation Announces Quarterly Cash Dividend Sealed Air Corporation (NYSE: SEE) has made a significant announcement regarding its commitment to shareholders. The company's Board of Directors has declared a quarterly cash dividend of $0.20 per common share. This decision reflects the company's strong financial performance and dedication to providing value to...

Continue Reading